✦ LIBER ✦

A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma

✍ Scribed by Sun Jin Sym; Dae Ho Lee; Hye Jin Kang; Seung Hyun Nam; Ho Young Kim; Seok Jin Kim; Hyeon Seok Eom; Won Seog Kim; Cheolwon Suh

Publisher: Springer
Year: 2008
Tongue: English
Weight: 292 KB
Volume: 64
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-008-0847-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of etoposide and cisplati

Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351

✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated

A phase II trial of oral etoposide with

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

✍ Jorge E. Romaguera; M. Alma Rodriguez; Frederick B. Hagemeister; Peter McLaughli 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 491 KB

Equitoxicity of bolus and infusional eto

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

✍ Carsten Zwick; Josef Birkmann; Norma Peter; Heinrich Bodenstein; Roland Fuchs; M 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 259 KB

A randomized trial of chemotherapy with

A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

✍ J.-P. Glossmann; A. Josting; B. Pfistner; U. Paulus; A. Engert; German Hodgkin's 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 90 KB

Single-dose palonosetron for prevention

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

✍ Nicola Di Renzo; Antonella Montanini; Donato Mannina; Alessandra Dondi; Stefania 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 141 KB

Four versus six courses of a dose-escala

Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation : Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma

✍ Nobert Schmitz; Marita Kloess; Marcel Reiser; Wolfgang E. Berdel; Bernd Metzner; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 252 KB